


Accepted Manuscript

Mevalonate pathway blockage enhances the efficacy of mTOR inhibitors with the activation of retinoblastoma protein in renal cell carcinoma

Nobuhisa Hagiwara, Motoki Watanabe, Mahiro Iizuka-Ohashi, Isao Yokota, Seijiro Toriyama, Mamiko Sukeno, Mitsuhiro Tomosugi, Yoshihiro Sowa, Fumiya Hongo, Kazuya Mikami, Jintetsu Soh, Akira Fujito, Hiroaki Miyashita, Yukako Morioka, Tsuneharu Miki, Osamu Ukimura, Toshiyuki Sakai



PII: S0304-3835(18)30356-2

DOI: [10.1016/j.canlet.2018.05.025](https://doi.org/10.1016/j.canlet.2018.05.025)

Reference: CAN 13909

To appear in: *Cancer Letters*

Received Date: 19 January 2018

Revised Date: 4 May 2018

Accepted Date: 15 May 2018

Please cite this article as: N. Hagiwara, M. Watanabe, M. Iizuka-Ohashi, I. Yokota, S. Toriyama, M. Sukeno, M. Tomosugi, Y. Sowa, F. Hongo, K. Mikami, J. Soh, A. Fujito, H. Miyashita, Y. Morioka, T. Miki, O. Ukimura, T. Sakai, Mevalonate pathway blockage enhances the efficacy of mTOR inhibitors with the activation of retinoblastoma protein in renal cell carcinoma, *Cancer Letters* (2018), doi: 10.1016/j.canlet.2018.05.025.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Abstract

Renal cell carcinoma (RCC) is the most common malignancy of kidney and remains largely intractable once it recurs after resection. mTOR inhibitors have been one of the mainstays used against recurrent RCC; however, there has been a major problem of the resistance to mTOR inhibitors, and thus new combination treatments with mTOR inhibitors are required. We here retrospectively showed that regular use of antilipidemic drug statins could provide a longer progression free survival (PFS) in RCC patients prescribed with an mTOR inhibitor everolimus than without statins (median PFS, 7.5 months vs. 3.2 months, respectively; hazard ratio, 0.52; 95% CI, 0.22-1.11). In order to give a rationale for this finding, we used RCC cell lines and showed the combinatorial effects of an mTOR inhibitor with statins induced a robust activation of retinoblastoma protein, whose mechanisms were involved in statins-mediated hindrance of KRAS or Rac1 protein prenylation. Finally, statins treatment also enhanced the efficacy of an mTOR inhibitor in RCC xenograft models. Thus, we provide molecular and (pre)clinical data showing that statins use could be a drug repositioning for RCC patients to enhance the efficacy of mTOR inhibitors.

Download English Version:

<https://daneshyari.com/en/article/8434256>

Download Persian Version:

<https://daneshyari.com/article/8434256>

[Daneshyari.com](https://daneshyari.com)